JP5232233B2 - 抗癌剤としてのキノリン誘導体を製造および投与する方法 - Google Patents
抗癌剤としてのキノリン誘導体を製造および投与する方法 Download PDFInfo
- Publication number
- JP5232233B2 JP5232233B2 JP2010521286A JP2010521286A JP5232233B2 JP 5232233 B2 JP5232233 B2 JP 5232233B2 JP 2010521286 A JP2010521286 A JP 2010521286A JP 2010521286 A JP2010521286 A JP 2010521286A JP 5232233 B2 JP5232233 B2 JP 5232233B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- quinoline
- mhz
- nmr
- methylquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 6
- 239000002246 antineoplastic agent Substances 0.000 title description 4
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title description 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- -1 quinoline derivative compound Chemical class 0.000 claims description 72
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- NBYLBWHHTUWMER-UHFFFAOYSA-N 2-Methylquinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(C)=CC=C21 NBYLBWHHTUWMER-UHFFFAOYSA-N 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 3
- OQXVXPBDSJQYRR-UHFFFAOYSA-N 8-methoxy-2-methylquinoline Chemical compound C1=C(C)N=C2C(OC)=CC=CC2=C1 OQXVXPBDSJQYRR-UHFFFAOYSA-N 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- 229960003540 oxyquinoline Drugs 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 3
- IXYZTQJBAJFGKP-UHFFFAOYSA-N 8-ethoxy-2-methylquinoline Chemical compound C1=C(C)N=C2C(OCC)=CC=CC2=C1 IXYZTQJBAJFGKP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- KUQKKIBQVSFDHX-UHFFFAOYSA-N 8-hydroxyquinoline-2-carbonitrile Chemical compound C1=C(C#N)N=C2C(O)=CC=CC2=C1 KUQKKIBQVSFDHX-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- 238000001819 mass spectrum Methods 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 23
- 125000000623 heterocyclic group Chemical group 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 125000002252 acyl group Chemical group 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000003480 eluent Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 229930013930 alkaloid Natural products 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 125000005017 substituted alkenyl group Chemical group 0.000 description 8
- 125000000547 substituted alkyl group Chemical group 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical compound C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 125000005415 substituted alkoxy group Chemical group 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- GMTGCIAJHZEUNB-UHFFFAOYSA-N 2-pentylquinoline Chemical compound C1=CC=CC2=NC(CCCCC)=CC=C21 GMTGCIAJHZEUNB-UHFFFAOYSA-N 0.000 description 2
- IZXJPGLOYYDHRM-UHFFFAOYSA-N 2-propylquinoline Chemical compound C1=CC=CC2=NC(CCC)=CC=C21 IZXJPGLOYYDHRM-UHFFFAOYSA-N 0.000 description 2
- SLBPIHCMXPQAIQ-UHFFFAOYSA-N 8-hydroxyquinoline-2-carbaldehyde Chemical compound C1=C(C=O)N=C2C(O)=CC=CC2=C1 SLBPIHCMXPQAIQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- LUMDXNLBIYLTER-UHFFFAOYSA-N Luotonin A Chemical compound C1=CC=C2C(=O)N(CC=3C4=NC5=CC=CC=C5C=3)C4=NC2=C1 LUMDXNLBIYLTER-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- LZLDOGIBLAERQI-UHFFFAOYSA-N chembl18395 Chemical compound C1=CC=C2C(=O)N3C(O)C4=CC5=CC=CC=C5N=C4C3=NC2=C1 LZLDOGIBLAERQI-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000007890 cytotoxin activity Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- SISLTKCJAXOJKK-UHFFFAOYSA-N 1,1-diphenyl-2-quinolin-2-ylethanol Chemical compound C=1C=C2C=CC=CC2=NC=1CC(O)(C=1C=CC=CC=1)C1=CC=CC=C1 SISLTKCJAXOJKK-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- PBMJZAANKKGYKC-UHFFFAOYSA-N 1-(1,2,3,4-tetrahydroquinolin-2-ylmethyl)cyclohexan-1-ol Chemical compound C1CC2=CC=CC=C2NC1CC1(O)CCCCC1 PBMJZAANKKGYKC-UHFFFAOYSA-N 0.000 description 1
- OLQALGSYDMMYMR-UHFFFAOYSA-N 1-(quinolin-2-ylmethyl)cyclohexan-1-ol Chemical compound C=1C=C2C=CC=CC2=NC=1CC1(O)CCCCC1 OLQALGSYDMMYMR-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- IHEQGRQCHGIUQE-UHFFFAOYSA-N 2,6-dimethyl-1,2,3,4-tetrahydroquinoline Chemical compound CC1=CC=C2NC(C)CCC2=C1 IHEQGRQCHGIUQE-UHFFFAOYSA-N 0.000 description 1
- AOQLKXDVZOCNOV-UHFFFAOYSA-N 2-(2-phenylethyl)-1,2,3,4-tetrahydroquinoline Chemical compound C1CC2=CC=CC=C2NC1CCC1=CC=CC=C1 AOQLKXDVZOCNOV-UHFFFAOYSA-N 0.000 description 1
- OKKXXGHSFMJXRJ-UHFFFAOYSA-N 2-(2-phenylethyl)quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1CCC1=CC=CC=C1 OKKXXGHSFMJXRJ-UHFFFAOYSA-N 0.000 description 1
- NTCUBKKLBPXCLQ-UHFFFAOYSA-N 2-but-3-enylquinoline Chemical compound C1=CC=CC2=NC(CCC=C)=CC=C21 NTCUBKKLBPXCLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- GVAZHZFKDJFLNN-UHFFFAOYSA-N 2-butyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2NC(CCCC)CCC2=C1 GVAZHZFKDJFLNN-UHFFFAOYSA-N 0.000 description 1
- GMZLALYCWQSOQS-UHFFFAOYSA-N 2-butylquinoline Chemical compound C1=CC=CC2=NC(CCCC)=CC=C21 GMZLALYCWQSOQS-UHFFFAOYSA-N 0.000 description 1
- KBEJREJHQMPXJD-UHFFFAOYSA-N 2-ethyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2NC(CC)CCC2=C1 KBEJREJHQMPXJD-UHFFFAOYSA-N 0.000 description 1
- XCIZVKSCLVSDHN-UHFFFAOYSA-N 2-ethylquinoline Chemical compound C1=CC=CC2=NC(CC)=CC=C21 XCIZVKSCLVSDHN-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- ZTQNUTNKGQGWCM-UHFFFAOYSA-N 2-methoxyquinoline Chemical compound C1=CC=CC2=NC(OC)=CC=C21 ZTQNUTNKGQGWCM-UHFFFAOYSA-N 0.000 description 1
- PDEJYMBYUUOXQA-UHFFFAOYSA-N 2-methyl-1,2,3,4-tetrahydroquinolin-8-ol Chemical compound C1=CC(O)=C2NC(C)CCC2=C1 PDEJYMBYUUOXQA-UHFFFAOYSA-N 0.000 description 1
- JZICUKPOZUKZLL-UHFFFAOYSA-N 2-methyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2NC(C)CCC2=C1 JZICUKPOZUKZLL-UHFFFAOYSA-N 0.000 description 1
- UXFLCJFXSJEMDX-UHFFFAOYSA-N 2-methyl-1-(1,2,3,4-tetrahydroquinolin-2-yl)propan-2-ol Chemical compound C1=CC=C2NC(CC(C)(O)C)CCC2=C1 UXFLCJFXSJEMDX-UHFFFAOYSA-N 0.000 description 1
- UTOMIKALKKLEJE-UHFFFAOYSA-N 2-methyl-1-quinolin-2-ylpropan-1-ol Chemical compound C1=CC=CC2=NC(C(O)C(C)C)=CC=C21 UTOMIKALKKLEJE-UHFFFAOYSA-N 0.000 description 1
- ZETRNHKIVLFOCA-UHFFFAOYSA-N 2-methyl-8-(2-piperidin-1-ylethoxy)quinoline Chemical compound C12=NC(C)=CC=C2C=CC=C1OCCN1CCCCC1 ZETRNHKIVLFOCA-UHFFFAOYSA-N 0.000 description 1
- IQPYORLIWUDPHP-UHFFFAOYSA-N 2-methyl-8-phenylmethoxyquinoline Chemical compound C12=NC(C)=CC=C2C=CC=C1OCC1=CC=CC=C1 IQPYORLIWUDPHP-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- COWWTNSCQZQEAB-UHFFFAOYSA-N 2-pentyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2NC(CCCCC)CCC2=C1 COWWTNSCQZQEAB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RTQBHSJQNWVSGE-UHFFFAOYSA-N 2-propyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2NC(CCC)CCC2=C1 RTQBHSJQNWVSGE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- BDCCXYVTXRUGAN-UHFFFAOYSA-N 6-fluoro-2-methyl-1,2,3,4-tetrahydroquinoline Chemical compound FC1=CC=C2NC(C)CCC2=C1 BDCCXYVTXRUGAN-UHFFFAOYSA-N 0.000 description 1
- FFNZAVKUPGTJAX-UHFFFAOYSA-N 6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline Chemical compound N1C(C)CCC2=CC(OC)=CC=C21 FFNZAVKUPGTJAX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RYXAGNHPWGDUPR-UHFFFAOYSA-N 8-amino-1h-quinolin-2-one Chemical compound C1=C(O)N=C2C(N)=CC=CC2=C1 RYXAGNHPWGDUPR-UHFFFAOYSA-N 0.000 description 1
- 150000004325 8-hydroxyquinolines Chemical class 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000189429 Angostura Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000159204 Peganum Species 0.000 description 1
- 235000005126 Peganum harmala Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JZOSBBLJKXSBBN-UHFFFAOYSA-N [3-(4-diphenylphosphanyl-2,6-dimethoxypyridin-3-yl)-2,6-dimethoxypyridin-4-yl]-diphenylphosphane Chemical compound COC=1N=C(OC)C=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1C=1C(OC)=NC(OC)=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 JZOSBBLJKXSBBN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DCVFYCPFXAEPSS-UHFFFAOYSA-N acetic acid 2-methoxyquinoline Chemical compound CC(O)=O.C1=CC=CC2=NC(OC)=CC=C21 DCVFYCPFXAEPSS-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229930002341 quinoline alkaloid Natural products 0.000 description 1
- WPYJKGWLDJECQD-UHFFFAOYSA-N quinoline-2-carbaldehyde Chemical compound C1=CC=CC2=NC(C=O)=CC=C21 WPYJKGWLDJECQD-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003530 tetrahydroquinolines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Description
eed Army Institute of Research/GlaxoSmit
GlaxoSmithKline plc)は、キノリン環を含むアルカロイドの一例であり、内臓リーシュマニア、リーシュマニア症の治療用の代替の経口薬として開発された。特に、8−ヒドロキシキノリンおよびその誘導体については、抗菌性が良好であり、神経組織変成疾患の治療を補助することが可能であると報告されている。また、この新規なキノリン塩およびその誘導体については、水溶性の上昇とともに抗腫瘍活性を与えることが報告されている。
さらに本発明では、固形腫瘍または非固形腫瘍の治療のために、薬学的に許容されるキャリア中のキノリン誘導体化合物を投与することを提供する。
一定の代表的な実施形態についての以下の記述は、単なる例であり、本発明、その用途、または使用を限定することを意図したものではない。本記載の全体を通じて、用語「アルキル」および「置換アルキル」は、1〜10の炭素原子を有する、直鎖、分岐鎖、または環式炭化水素基などの基を表す。これらのアルキル基は、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、tert−ブチル、ペンチル、ヘキシル、ヘプチル、オクチル、ノニル、デシル、シクロプロピル、シクロブチル、シクロペンチル、またはシクロヘキシルである。
ールグリオキシロイル(フェニルグリオキシロイル、ナフチルグリオキシロイルなど);アリールスルホニル(フェニルスルホニル、ナフチルスルホニルなど);複素環式カルボニル、複素環式アルカノイル(チエニルアセチル、チエニルプロパノイル、チエニルブタノイル、チエニルペンタノイル、チエニルヘキサノイル、チアゾリルアセチル、チアジアゾリルアセチル、テトラゾリルアセチルなど)、複素環式アルケノイル(複素環式プロペノイル、複素環式ブテノイル、複素環式ペンテノイル、または複素環式ヘキセノイルなど)、または複素環式グリオキシロイル(チアゾリルグリオキシロイルまたはチエニルグリオキシロイルなど)である。
用語「ヒドロキシル」は、酸素原子に結合している水素を表し、用語「置換ヒドロキシル」は、1つ以上の基(ハロゲン、保護されたヒドロキシル、シアノ、ニトロ、アルキルまたは置換アルキル、アルケニルまたは置換アルケニル、アシルまたは置換アシル、アリールまたは置換アリール、ヘテロ環または置換ヘテロ環、アルコキシまたは置換アルコキシ、アシルオキシまたは置換アシルオキシ、カルボキシまたは保護されたカルボキシ、カルボキシメチルまたは保護されたカルボキシメチル、ヒドロキシメチルまたは保護されたヒドロキシメチル、アミノまたは保護されたアミノ、カルボキサミドまたは保護されたカルボキサミドなど)によって置換されたヒドロキシル基を表す。
用語「スルホニル」および「置換スルホニル」は、−S(O)2−を含む基(例えば、メチルスルホニル、エチルスルホニル、プロピルスルホニル、トリフルオロメタンスルホニル、トリクロロメタンスルホニル、または他のハロゲン置換アルキルスルホニルもしくはアリールスルホニル)を表す。
ば、メチルスルフィニル、エチルスルフィニル、ブチルスルフィニル、ヘキシルスルフィニル)を表す。
本発明において、調製および使用に用いられる化合物には、式I〜IVによって表されるものおよびその塩が含まれる。
がABCD環およびWXYZ環の部位に2度以上現れてもよく、R1/R2の両方が特定のキラル置換基であってもよい。
2−エチル−キノリン
.0Hz),8.07(t,2H,J=8.5Hz);13C−NMR(125MHz,CDCl3):δ14.26,22.81,30.02,31.99,39.53,121.62,125.91,126.95,127.72,128.96,129.61,136.52,148.01,163.36;質量スペクトル(ESI):200.16[M+H]+;収率=91%。
;HPLC(OJ−H,溶出液:ヘキサン/i−PrOH=95/5,検出器:254nm,流速:0.5mL/min),(S)t1=25.6min,(R)t2=28.7min。
4nm,流速:0.5mL/min),(S)t1=24.2min,(R)t2=29.8min。
),1.50−1.69(m,3H),1.75−1.80(m,1H),2.63−2.68(m,2H),2.77−2.84(m,1H),3.48−3.52(m,1H),6.43(d,1H,J=8.0Hz),6.53(t,1H,J=7.5Hz),6.88(t,2H,J=7.5Hz);13C−NMR(125MHz,CDCl3):δ26.78,28.04,29.96,33.02,48.56,49.12,72.20,114.85,117.15,121.33,126.96,129.51,144.62;質量スペクトル(ESI):205.84[M+H]+;95%ee;HPLC(OD−H,溶出液:ヘキサン/i−PrOH=94/6,検出器:254nm,流速:1.0mL/min),(S)t1=9.0min,(R)t2=11.1min。
[実施例1]:8−ヒドロキシ−2−キノリンカルボキサルデヒドの合成
物をシリカゲルカラムクロマトグラフィによって精製して、無色の油分として定量的にアルコール生成物を得た。
2.配位子はP−Phosおよびその誘導体であってもよく、他のホスフィン配位子であってもよく、任意の可能な種類の配位子であってよい。
選択したアルカロイドについての予備抗癌スクリーニングの目的で、ヒト胸癌細胞系T47Dおよび慢性骨髄性白血病(CML)K562を用いた。96ウェルマイクロタイター(microtitre)プレートに24時間接種した癌細胞(ウェルあたり1×104)を、アルカロイドスクリーニング用に調製した。化合物a〜g(図1)を、ジメチルスルホキシド(DMSO)中、ストック濃度50mg/mlとして調製し、50μg/mlの濃度で加え、さらに48時間、インキュベートした。未処理のコントロールには、完全培地または0.1%のDMSOのいずれかを与えた。シスプラチン(CDDP、やはり50μg/ml)を陽性の基準とした。その後、それらのアルカロイドの抗増殖性または細胞毒性の評価を、PerkinElmerから購入したOneStepATPライトアッセイを用いて、与えられた技術マニュアルに従って検査した。各実験において3回の試験を行い、3つの独立した実験を行った。未処理のコントロールと比較したATP含有量の中間値±標準偏差(SD)として結果を示す。テーブル2には、試験済みのアルカロイド関連化合物の細胞毒性アッセイを示す。シスプラチン(CDDP)を陽性の基準として用いる。試験化合物およびCDDPの濃度はすべて、50μg/mlである。結果を、3回の実験からの中間値±SDとして示す。
ヒト胸癌細胞系Hs578t、T47D、および慢性骨髄性白血病K562を、モルホロジ調査の目的で用いた。培養皿に24時間接種した癌細胞(1×105)を、アルカロイドスクリーニング用に調製した。テーブル1の化合物cを、25μg/mlの濃度で加え、さらに48時間インキュベートした。未処理のコントロールには0.05%のDMSOを与えた。任意のモルホロジ変化を倒立顕微鏡下で記録した。図2に示すように、3つの癌細胞系すべてが細胞収縮を示し、2本の胸癌細胞系は付着性も喪失し、細胞が丸くなるのが観察された(d、e、f)。DMSOコントロールでは正常な成長が観察された(a、b、c)。
図3に示すように、ヒト乳癌細胞系T47Dを培養板に1×105/mlの濃度で24時間接種した。後に、様々な濃度の化合物cを加えた。未処理のコントロール(0)には、0.1%のDMSOを与えた。さらなる24時間のインキュベーション後、培地をすべて除去し、新鮮な完全な培地を加えた。培養板をさらに7日間インキュベートした。最終的に、形成されたコロニーを固定し、メチレンブルーで染色し、写真を撮影した。ここでの結果は、T47D細胞の固定によるクローン原性を化合物cが用量に応じて抑制し得ることを示している。
香港中文大学(the Chinese Univercity of Hong Kong)の動物部(animal house)から購入された平均体重25gの無胸腺のヌードマウスに、ヒト肝細胞(HCC)細胞系Hep3Bを皮下注射した。それらのマウスを滅菌状態で収容した。腫瘍サイズを電子的なカリパスによって毎日測定した。腫瘍サイズが平均体積の約150mm3に達したとき(腫瘍体積は式(長さ×幅×幅)/2によって算出した)、それらを無作為に2つの群へ分けた。テーブル1の化合物cを10mg/kg/日体重の濃度で、8日間連続して腹腔内注入で投与した。コントロール群にはキャリアのみを与えた。各群は5つのマウスから構成した。図4および5に示すように、
化合物cを与えたマウスにおいて、薬剤の投与から9日目に肝細胞癌Hep3B異種移植片がほぼ完全に消失するのが観察された。
Claims (6)
- 癌の治療用の医薬組成物であって、該医薬組成物はキノリン誘導体化合物を含み、該キノリン誘導体化合物は、8−ヒドロキシ−2−キノリンカルボキサルデヒド、8−ヒドロキシ−2−メチルキノリン、8−メトキシ−2−メチルキノリン、8−ヒドロキシ−2−キノリンカルボニトリル、8−ヒドロキシキノリン、8−エトキシ−2−メチルキノリン、8−(2−ピペリジン−1−イル)エトキシ)−2−メチルキノリンから選択される、医薬組成物。
- 前記癌は固形腫瘍または非固形腫瘍である、請求項1に記載の医薬組成物。
- 前記医薬組成物は、ポリエチレングリコール、CMC、または任意の永続的に結合したキャリア剤である薬学的に許容されるキャリア中に含まれ、哺乳動物に対し該哺乳動物の体重の8mg/kg/日〜約12mg/kg/日の量で投与される、請求項1に記載の医薬組成物。
- 前記医薬組成物は5〜10日間連続して投与される、請求項3に記載の医薬組成物。
- 前記癌は胸癌、肝細胞癌、または慢性骨髄性白血病である、請求項1に記載の医薬組成物。
- 癌の治療用の医薬組成物を製造する方法であって、
前記医薬組成物に含まれるキノリン誘導体化合物の溶液に試薬の溶液を加える工程と、
前記試薬/キノリン溶液を適切な温度まで加温する工程と、
反応が完了するまで適切な時間、撹拌する工程と、
前記溶液にさらなる試薬を加える工程と、
撹拌、加水分解、水素化、分離、抽出、洗浄、乾燥、希釈、および精製から選択される1つ以上の追加の処理を行う工程と、を含み、
前記キノリン誘導体化合物は、8−ヒドロキシ−2−キノリンカルボキサルデヒド、8−ヒドロキシ−2−メチルキノリン、8−メトキシ−2−メチルキノリン、8−ヒドロキシ−2−キノリンカルボニトリル、8−ヒドロキシキノリン、8−エトキシ−2−メチル
キノリン、8−(2−ピペリジン−1−イル)エトキシ)−2−メチルキノリンから選択される、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/892,188 US9321730B2 (en) | 2007-08-21 | 2007-08-21 | Method of making and administering quinoline derivatives as anti-cancer agents |
US11/892,188 | 2007-08-21 | ||
PCT/CN2008/072092 WO2009024095A1 (en) | 2007-08-21 | 2008-08-21 | Method of making and administering quinoline derivatives as anti-cancer agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010536805A JP2010536805A (ja) | 2010-12-02 |
JP5232233B2 true JP5232233B2 (ja) | 2013-07-10 |
Family
ID=40377876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010521286A Active JP5232233B2 (ja) | 2007-08-21 | 2008-08-21 | 抗癌剤としてのキノリン誘導体を製造および投与する方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9321730B2 (ja) |
EP (1) | EP2188259B1 (ja) |
JP (1) | JP5232233B2 (ja) |
CN (1) | CN101868447B (ja) |
WO (1) | WO2009024095A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9321730B2 (en) | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
US9493419B2 (en) | 2007-08-21 | 2016-11-15 | The Hong Kong Polytechnic University | Quinoline derivatives as anti-cancer agents |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
JP2016507551A (ja) | 2013-02-13 | 2016-03-10 | ファイザー・インク | ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
WO2015034820A1 (en) * | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
MA39866A (fr) | 2014-04-10 | 2017-02-15 | Pfizer | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle |
KR102100470B1 (ko) | 2015-08-21 | 2020-04-13 | (주)오토파지사이언스 | 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
EP3353174A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors |
JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド |
CN105399669B (zh) * | 2015-11-27 | 2019-05-03 | 中国药科大学 | 一种二羟基异喹啉及其从蜈蚣中制备的方法和应用 |
CN111471012B (zh) * | 2019-01-23 | 2023-04-25 | 鲁南制药集团股份有限公司 | 一种蜈蚣喹啉类化合物、制备方法及其应用 |
CN110638846B (zh) * | 2019-09-24 | 2021-08-03 | 北京大学深圳研究生院 | RNase L抑制剂的应用 |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
EP4175719A1 (en) | 2020-07-02 | 2023-05-10 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
JPH0597674A (ja) | 1991-10-01 | 1993-04-20 | Nikko Kyodo Co Ltd | コラーゲナーゼ阻害剤 |
FR2682107B1 (fr) * | 1991-10-03 | 1995-04-21 | Orstom Inst Fs Rech Scient | Quinoleines 2-substituees pour le traitement des leishmanioses. |
WO1997044036A1 (en) | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
JPH10176053A (ja) | 1996-12-19 | 1998-06-30 | Sumitomo Chem Co Ltd | フェノール縮合物の製造方法 |
AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
GB0414639D0 (en) | 2004-06-30 | 2004-08-04 | Elam T Ltd | Electroluminescent materials and devices |
CN101589026B (zh) | 2006-06-22 | 2013-10-16 | 普拉纳生物技术有限公司 | 治疗脑神经胶质瘤的方法 |
US20100150844A1 (en) | 2006-07-28 | 2010-06-17 | The Johns Hopkins University | Use of 8-quinolinol and its analogs to target cancer stem cells |
US9321730B2 (en) | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
-
2007
- 2007-08-21 US US11/892,188 patent/US9321730B2/en active Active
-
2008
- 2008-08-21 WO PCT/CN2008/072092 patent/WO2009024095A1/en active Application Filing
- 2008-08-21 JP JP2010521286A patent/JP5232233B2/ja active Active
- 2008-08-21 CN CN200880110440.5A patent/CN101868447B/zh active Active
- 2008-08-21 EP EP08784083.1A patent/EP2188259B1/en not_active Not-in-force
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9321730B2 (en) | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
US9493419B2 (en) | 2007-08-21 | 2016-11-15 | The Hong Kong Polytechnic University | Quinoline derivatives as anti-cancer agents |
Also Published As
Publication number | Publication date |
---|---|
EP2188259A1 (en) | 2010-05-26 |
EP2188259B1 (en) | 2013-11-06 |
CN101868447A (zh) | 2010-10-20 |
EP2188259A4 (en) | 2011-08-17 |
JP2010536805A (ja) | 2010-12-02 |
CN101868447B (zh) | 2012-11-07 |
WO2009024095A1 (en) | 2009-02-26 |
US20090054482A1 (en) | 2009-02-26 |
US9321730B2 (en) | 2016-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5232233B2 (ja) | 抗癌剤としてのキノリン誘導体を製造および投与する方法 | |
US9493419B2 (en) | Quinoline derivatives as anti-cancer agents | |
US20210052575A1 (en) | Piperazine-substituted benzothiophene derivatives as antipsychotic agents | |
WO1999021849A1 (fr) | Procedes servant a preparer des derives 7-isoindolinequinolonecarboxyliques et leurs intermediaires, sels d'acides 7-isoindolinequinolonecarboxyliques, leurs hydrates, compositions les contenant en tant qu'ingredients actifs | |
JP7000537B2 (ja) | 医薬 | |
CN104725363B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
JP2014062103A (ja) | 治療用キノリンおよびナフタレン誘導体 | |
CN114392262B (zh) | 抑制神经系统退行性疾病的白桦脂酸衍生物 | |
US20240002378A1 (en) | Merged scaffold taf1 inhibitors | |
JP2024500249A (ja) | Enpp1およびcdnpの阻害剤としてのホスホネート類 | |
CN116600813A (zh) | 作为enpp1和cdnp抑制剂的膦酸盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100924 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100924 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130322 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160329 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5232233 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |